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Abstract: The steady increase in the average life-expectancy in the developed world can be attributed in part
at least, to advances in virtually all areas of medicine, starting with technological advances in diagnostic
techniques, greater awareness as regards living a healthy lifestyle, more efficient surgery protocols, while less
invasive methods are used whenever possible, a greater depth of the etiology and pathogenesis of the disease
and so on and so forth. However, despite overcoming a great number of illnesses, other formidable diseases
still remain unscathed by even the most aggressive treatment. This seems to be the point in fact, where the
promise of stem cells becomes more exciting and poignant. Research investigating the potential use of stem
cells against these illnesses yielded a number of encouraging results and even successful therapy protocols
in some instances (ex. leukaemia). Some therapies are also in the pipeline while others are still experimental.
Having said this, the material available today gives an encouraging boost for all involved in the fight against
some of the debilitating and ruthless illnesses of our times.
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INTRODUCTION mutations, leading to a change in function as well as
Stem cells are defined as “clonogenic self-renewing tests for brain tumours focus on all cells, instead of
progenitor cells that have the ability to divide from an specifically attacking the cells which lead to the
indefinite period and can give rise to one or more uncontrolled growth, in other words the tumour stem
differentiated cell types” (Vejjajiva, 2002), which ability is cells.  This  could  explain  the  poor  rate  of  response  of
known as developmental plasticity. the tumours to treatment. 
The plasticity varies in the different types of stem The  first  isolation of cancer stem cells from the
cells. The zygote gives rise to all cell types and normally central  nervous  system  was  performed by Dr. Peter
develops into an embryo. It is said to be totipotent. Dirks and Dr. Sheila Singh, at the University of Toronto
Embryonic and umbilical stem cells also give rise to all cell (Singh et al., 2003). 
types. However given that they are not able to develop The approach used primary human brain tumours,
into an embryo, they are described as pluripotent. Finally obtained from neurosurgical operations, from which the
adult stem cells show a range of plasticity from pluri-to team isolated and characterized a cancer stem cell from
multipotent with mesenchymal cells being able to give rise human brain tumours of different phenotypes, more
to lipocytes, cartilage, bone, tendon and ligaments, specifically low grade and high grade primary brain
myocytes, skin cells and neurons, while haematopoeitic tumours consisting of astrocytomas, glioblastomas,
stem cells are able to give rise to red, white blood cells, ependymomas, medulloblastomas, angliogliomas (Fig. 1).
immune cells among others. Transdifferentiation (the The isolated cells express neural stem cell markers, have
crossing of germ layers) is also possible. stem cell-like behaviour in vitro and represent only a small
This amazing range of plasticity of stem cells has fraction of the total tumour cell population. 
given hope in the fight against conditions as diverse as Given  that  these  cancer  stem  cells are necessary
brain tumours, neurodegenerative diseases, spinal injuries for maintaining tumour growth in vitro, their identification
and amazingly, also in the regeneration of tissue, such as has important implications for understanding the
in liver and kidney, to name just two examples. mechanisms  of  brain   tumorigenesis.   Furthermore,
Cancer- brain tumours: As in all cancers, brain tumour total number of cells in a brain tumour (Reynolds and
cells arise from normally functioning cells which undergo Weiss,  1996;  Morshead  et   al.,  1994)   results   obtained
uncontrolled proliferation of the tumour cells. Current
since this cell represents only a small proportion of the
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Fig. 1: Primary brain tumours of different phenotypes form neurosphere-like colonies. Photomicrographs of cultured
brain tumour cells (magnification × 20) at 24-48 h after plating in TSM (Tumour Sphere Medium), containing EGF
(Epidermal Growth Factor) and bFGF (basic Fibroblast Growth Factor). Each tumour subtype yielded growth of
cells in neurosphere-like clusters, termed tumour spheres
suggested that therapy that spares this cell may explain mentioned above, Yasuhara and her team tried to
tumour recurrence. establish whether transplantation of human NSCs cloned
Hence, it follows, that if the said finding were to be by v-myc gene transfer, HB1.F3 cells, is a feasible
borne out by future research, it could offer a potential new therapeutic option for Parkinson's disease. This was done
approach to fighting brain tumours, by targeting brain by transplanting green fluorescent protein-labelled
tumour stem cells and thus stopping the growth and HB1.F3 cells (200,000 viable cells in  3 microl of PBS) in
spread of the cancer (Singh et al., 2003). vivo, into the 6-hydroxydopamine-lesioned striatum of
Tumour spheres are shown from a medulloblastoma rats. It was in fact established that this procedure
(A), pilocytic astrocytoma (B), ependymoma (C) and significantly ameliorated parkinsonian behavioural
ganglioglioma (D). Undifferentiated primary tumor spheres symptoms, when compared with controls (vehicle, single
from a medulloblastoma (E, F, I and J) and a pilocytic bolus, or continuous minipump infusion of trophic factor,
astrocytoma (G, H, K and L) are immunostained at 4 h for or killed cell grafts). 
characteristic neural stem cell marker nestin (E and G) and In another project, mesencephalic precursor cells
for CD133 (F and H). Individual undifferentiated were studied in more detail, given that to date, the
medulloblastoma sphere cells and astrocytoma sphere generation of dopaminergic neurons from mesencephalic
cells are also shown stained for nestin (I and K) and precursors has been difficult to follow, partly because an
CD133 (J and L) (Singh et al., 2003). appropriate means for recognizing mesencephalic
NEURODEGENERATIVE DISORDERS overcome his difficulty, Sawamoto’s team used transgenic
Parkinson’s Disease (PD): PD seems to be ideal for stem cDNA under the control of the nestin enhancer, in order
cell treatment, given that the main pathology is a relatively to visualize and isolate mesencephalic precursor cells from
selective degeneration of a specific type of neuron, the a mixed population. From the results, it can be seen that
nigrostriatal dopamine neuron. This is as opposed to nestin-driven GFP was detected in the mesencephalic
ischeamic disease, as in for example stroke, or Alzheimer’s ventricular  zone.  Additionally,   data   obtained  from
disease. flow-cytometry   indicated    that     Prominin/CD133,   a
Neural Stem Cells (NSCs) exhibit high potencies of cell-surface marker for ventricular zone cells, was
self-renewal  and  neuronal   differentiation.  Hence, expressed specifically in these GFP-positive (GFP(+))
various research projects have been conducted in order cells. These cells were cultured in vitro, after sorting by
to try to understand in greater depth the complex fluorescence-activated cell sorting. The sorted population
processes involved in neuronal development and was shown to be able differentiate into both neurons and
ultimately to find a cure for PD. Thus, in the project glia.  Furthermore,  many  neurons   generated  from
ventricular zone precursors has not been available. To
mice and rats carrying Green Fluorescent Protein (GFP)
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nestin-GFP-sorted mesencephalic precursors developed repair of the spinal cord have been conducted in
a dopaminergic phenotype in vitro and were, in fact, were experimental injury models and their potential for human
able to restore dopaminergic function in the host striatum, application was studied (Nandoe et al., 2006). 
as assessed by a behavioral measure: recovery from In another research project, given that the injured
amphetamine-induced rotation, when they were adult spinal cord is not conducive to neuronal
transplanted into the striatum of a rat model of Parkinson's regeneration and neurogenesis, attempts were made to
disease (Sawamoto et al., 2001). enhanced neurogenesis or oligodendroglia differentiation
Both these functions indicate that stem cells give of transplanted Neural Precursor Cells (NPCs) by genetic
promising results in providing treatment for PD when manipulation, such as for example the exogenous
used in protocols in the lab. expression of noggin, with the idea of antagonizing the
Alzheimer’s Disease (AD): To date, much evidence has Proteins (BMPs). Direct attempts to enhance
become available, to the effect that the brain is capable of neurogenesis have also been made in transgenic over-
regenerating neurons after maturation. In a recent study, expression of neurogenic basic helix-loop-helix
Human Neural Stem Cells (HNSCs) transplanted into aged transcription factors (Tang and Law, 2007). Having said
rat brains differentiated into neural cells. Furthermore, this, it is important to keep in mind that successful repair
they significantly improved the cognitive functions of the of the spinal cord requires the development of in vitro
animals, indicating that HNSCs may be a promising techniques that will generate the desired cell type and/or
candidate for cell-replacement therapies for a large enough number for in vivo transplantation
neurodegenerative diseases including AD (Sugaya et al., approaches. 
2006). However, HNSC have been a source of ethical
controversy, leading the same group of researchers to ORGAN REGENERATION
explore novel technologies to differentiate adult human
mesenchymal stem cells, a subset of stromal cells in the Kidney: Unlike in other areas (as in leukaemia for
bone marrow, into neural cells by modifying DNA example), in nephrology the use of stem cell therapy has
methylation or over expression of nanog, a homeobox yet to reach practical therapeutics applications. In fact, no
gene expressed in embryonic stem cells. The study, which one as yet has coaxed bone marrow stem cells to become
was published some time after, reported that peripheral renal cells although the local presence of renal adult stem
administrations of a pyrimidine derivative that increases cell-like cells has been confirmed (Humes et al., 1999).  It
endogenous stem cell proliferation, improves cognitive sees that while the initial work by Humes and his
function of the aged animal (Sugaya et al., 2006). colleagues in Ann Arbor Michigan USA in the years
Although these results may promise a bright future 1996-2001 enjoyed some degree of success, in the last few
for clinical applications used towards stem cell strategies years the  interest  and  promise  have  waned.  Having
in AD therapy, it is important to keep in mind the fact that said this, it is worth noting that Humes and colleagues
AD is complex, as all pathological processes. Hence, while were able to build a biosynthetic renal tubule assist
these results are encouraging, more work needs to be device where the synthetic fibres were coated with
done before it can be successfully treated. porcine tubular cells that appeared to mimic certain
Spinal injury: Impaction of the spinal cord results in the synthesis and activation of vitamin D (Humes et al.,
immediate damage to various tissue types, including 1999).
blood vessels, as well as nercous tissue, causing loss of Poulsom (2001) examined kidneys of female mice that
neurons, astrocytes and oligodendrocytes. In time, had received a male bone marrow transplant and kidney
secondary injury may result causing more tissue nearby biopsies from male patients who had received kidney
or away from the injury site to be lost. Although, in case transplants from female donors, in order to establish
of relatively minor damage to the cord, some return of whether extra-renal cells contribute to the turnover and
function can be observed, in most cases the neurological repair of renal tissues. The method used in situ
loss is permanent. hybridization to detect Y-chromosomes, after which it
Stem cells have a high potential for regeneration and could be demonstrated that circulating stem cells
have in fact, been implicated in repair of the adult spinal frequently engraft into the kidney and differentiate into
cord. in vitro and in vivo studies on the use of BMSCs for renal parenchymal cells. 
astroglia differentiation promoting Bone Morphogenetic
biochemical  properties  of  the  human  kidney,  such  as
Res. J. Med. Sci., 2 (1): 47-50, 2008
50
When this was applied to human renal grafts, it was REFERENCES
confirmed that some of the recipient-derived cells within
the kidney exhibited a tubular epithelial phenotype, by
combining in situ hybridization with immunostaining for
the epithelial markers CAM 5.2 and the lectin Ulex
europaeus.  Furthermore,  female  mouse recipients of
male  bone  marrow  grafts  showed   co-localization   of
Y-chromosomes  and tubular epithelial markers Ricinus
communis and Lens culinaris and a specific cytochrome
P450 enzyme (CYP1A2) indicating an appropriate
functional capability of clustered newly formed marrow-
derived tubular epithelial cells. Y-chromosome-containing
cells were observed within glomeruli, with morphology
and location appropriate for podocytes, while within the
murine kidney, these Y-chromosome-positive cells were
negative for the mouse macrophage marker F4/80 antigen
and leukocyte common antigen, but were vimentin-
positive. Bone marrow-derived cells were present in both
histologically normal mouse kidneys and in human
transplanted kidneys suffering damage from a variety of
causes. This data indicates that bone marrow cells
contribute to both normal turnover of renal epithelia and
regeneration after damage (Poulsom et al., 2001).
More recently, research performed at Yale and the
London hospitals confirming the importance of the bone
marrow  in  tubulogenesis  and  the  recovery of acute
renal failure have provided indirect evidence to the
presence  of  potential  renal  cells  in  the  bone marrow
and may open the door to harvesting such cells for future
use, given the fact that data from experimental animal
models of renal diseases have shown that infused bone
marrow-derived SC may repair the injured glomeruli
(Schena and Abbattista, 2003).
At present the production of a biosynthetic human
kidney to treat patients with chronic renal failure remains
a dream.  
CONCLUSION
While on the one hand the promise of stem cells is
undeniable, especially given the fantastic results achieved
experimentally, it is important to note that a lot needs to
be done before most of the therapies based on stem cells
are available on the market.
Illnesses like brain tumours, renal failures and
neurodegenerative disorders seem set to continue to
feature prominently in the years to come as the population
continues to age. Hence, it is vital for solutions to be
researched thoroughly in the interest of patients, their
relatives and ultimately the whole of humanity.
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